<DOC>
	<DOCNO>NCT00717704</DOCNO>
	<brief_summary>Patients ask take part study diagnose advanced solid tumor respond standard treatment . This study find high dose ixabepilone dasatinib combination give without cause severe side effect . Both ixabepilone dasatinib individually test many ( several thousand ) patient , however combination two drug yet test human . All patient take part study receive combine drug therapy dasatinib ixabepilone . Dasatinib pill take mouth . Ixabepilone medicine give vein ( IV ) . All participant receive ixabepilone vein every three week well dasatinib mouth daily .</brief_summary>
	<brief_title>Solid Tumors Using Ixabepilone Dasatinib</brief_title>
	<detailed_description />
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Have solid tumor malignancy metastatic locally advanced/unresectable Progression standard therapy Histological documentation cancer Must prior chemotherapy radiation therapy least 3 week Must adequate organ marrow function prior start study treatment define protocol Must able swallow oral medication ( dasatinib must swallow whole ) Must available protocolrequired followup Patients malignancy ( one treat study ) require radiotherapy systemic therapy within past 5 year Symptomatic brain metastasis either untreated uncontrolled surgery radiotherapy A known , prior , severe ( NCI CTC Grade 3/Grade 4 ) history hypersensitivity reaction drug formulate Cremophor ( polyoxyethylated castor oil ) A serious , uncontrolled medical disorder active infection include pericardial pleural effusion grade , uncontrolled significant cardiovascular disease , bleed disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Malignant solid tumor</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Metastatic locally advanced/unresectable</keyword>
	<keyword>Disease progression standard therapy</keyword>
</DOC>